267 related articles for article (PubMed ID: 26831742)
21. Subnational responsibilities for healthcare and Austria's rejection of the EU's patients' rights directive.
Kostera T
Health Policy; 2013 Jul; 111(2):149-56. PubMed ID: 23602349
[TBL] [Abstract][Full Text] [Related]
22. From DTCA-PD to patient information to health information: the complex politics and semantics of EU health policy.
Brooks E; Geyer R
J Eval Clin Pract; 2012 Dec; 18(6):1235-40. PubMed ID: 22816868
[TBL] [Abstract][Full Text] [Related]
23. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
Alván G
Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
[No Abstract] [Full Text] [Related]
24. Europeanisation of health systems: a qualitative study of domestic actors in a small state.
Azzopardi-Muscat N; Sorensen K; Aluttis C; Pace R; Brand H
BMC Public Health; 2016 Apr; 16():334. PubMed ID: 27079508
[TBL] [Abstract][Full Text] [Related]
25. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?
Boráň T; Menezes-Ferreira M; Reischl I; Celis P; Ferry N; Gänsbacher B; Krafft H; Lipucci di Paola M; Sladowski D; Salmikangas P
Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497
[TBL] [Abstract][Full Text] [Related]
26. [The 12th amendment to the German Drug Law. Chances and obstacles for investigator-initiated clinical trials].
Dreier G; Marx C; Schmoor C; Maier-Lenz H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):445-52. PubMed ID: 15830256
[TBL] [Abstract][Full Text] [Related]
27. Establishing pan-European clinical trials: regulatory compliance and other practical considerations.
Grienenberger A
J Biolaw Bus; 2004; 7(4):58-63. PubMed ID: 15675097
[TBL] [Abstract][Full Text] [Related]
28. Moving the boundaries of international collaboration on clinical trials and QoL: experiences in oncology and legislation within the European Parliament.
Bottomley A; Kirby T; Bean J; Walker J
Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):43-5. PubMed ID: 23402444
[TBL] [Abstract][Full Text] [Related]
29. European Union health policy and its implications for national convergence.
Cucic S
Int J Qual Health Care; 2000 Jun; 12(3):217-25. PubMed ID: 10894193
[TBL] [Abstract][Full Text] [Related]
30. Biomedical patents and the public's health: is there a role for eminent domain?
Kesselheim AS; Avorn J
JAMA; 2006 Jan; 295(4):434-7. PubMed ID: 16434634
[No Abstract] [Full Text] [Related]
31. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
Adamini S; Maarse H; Versluis E; Light DW
J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
[TBL] [Abstract][Full Text] [Related]
32. PUBLIC PROCUREMENT IN THE HEALTHCARE SECTOR: ADAPTATION OF THE ADMINISTRATIVE LEGISLATION OF UKRAINE TO THE EU LEGISLATION.
Deshko L; Bysaga Y; Bysaga Y
Georgian Med News; 2019 Jun; (291):126-130. PubMed ID: 31418745
[TBL] [Abstract][Full Text] [Related]
33. Neither protective nor harmonized: the crossborder regulation of medical devices in the EU.
Jarman H; Rozenblum S; Huang TJ
Health Econ Policy Law; 2021 Jan; 16(1):51-63. PubMed ID: 32631465
[TBL] [Abstract][Full Text] [Related]
34. [Regulation (EU) No 536/2014 on Clinical Trials and Vulnerable Groups].
Mariño Hernández EL
Cuad Bioet; 2015; 26(88):427-30. PubMed ID: 26546797
[TBL] [Abstract][Full Text] [Related]
35. A prospective view on European pharmaceutical research and development. Policy options to reduce fragmentation and increase competitiveness.
Kanavos P
Pharmacoeconomics; 1998 Feb; 13(2):181-90. PubMed ID: 10178646
[TBL] [Abstract][Full Text] [Related]
36. The emerging EU quality of care policy: from sharing information to enforcement.
Vollaard H; van de Bovenkamp HM; Vrangbæk K
Health Policy; 2013 Aug; 111(3):226-33. PubMed ID: 23764152
[TBL] [Abstract][Full Text] [Related]
37. An anthropological analysis of European Union (EU) health governance as biopolitics: the case of the EU tissues and cells directive.
Hoeyer K
Soc Sci Med; 2010 Jun; 70(12):1867-1873. PubMed ID: 20378227
[TBL] [Abstract][Full Text] [Related]
38. Germany opposes EU plans for regulating clinical trials owing to lack of ethical standards.
Tuffs A
BMJ; 2012 Oct; 345():e6640. PubMed ID: 23033377
[No Abstract] [Full Text] [Related]
39. Health, federalism and the European Union: lessons from comparative federalism about the European Union.
Greer SL
Health Econ Policy Law; 2021 Jan; 16(1):90-103. PubMed ID: 32349829
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
